Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 6—June 2011
Dispatch

Salmonella enterica Serotype Typhi with Nonclassical Quinolone Resistance Phenotype

Marie Accou-Demartin, Valérie Gaborieau, Yajun Song, Philippe Roumagnac, Bruno Marchou, Mark Achtman, and François-Xavier WeillComments to Author 
Author affiliations: Author affiliations: Institut Pasteur, Paris, France (M. Accou-Demartin, F.-X. Weill); Hôpital Purpan, Toulouse, France (V. Gaborieau, B. Marchou); University College Cork, Cork, Ireland (Y. Song, M. Achtman); Centre de Coopération International en Recherche Agronomique pour le Développement, Montpellier, France (P. Roumagnac)

Main Article

Table 2

Characteristics of the 11 Salmonella enterica serovar Typhi isolates belonging to subpopulation B, France, 2007–2009

Isolate Year Geographic origin Antimicrobial drug resistance type Disk diffusion, mm
MIC, μg/mL
gyrB Haplotype PFGE
Nal Cip Nal Cip
97-5123 1997 Unknown CipDS 18 [I] 28 [S] 8 [S/S] 0.125 [S/S] Tyr464 Non-H58 X8
02-2759 2002 India CipDS 19 [I] 26 [S] 4 [S/S] 0.125 [S/S] Phe464 H58 X2
05-1578 2005 India Pansusceptible 18 [I] 28 [S] 8 [S/S] 0.047 [S/S] Asp466 Non-H58 X6
05-2556 2005 India CipDS 17 [I] 31 [S] 16 [I/S] 0.19 [S/S] Phe464 Non-H58 X7
05-9141 2005 India CipDS 17 [I] 28 [S] 12 [I/S] 0.125 [S/S] Tyr464 Non-H58 X3
06-426 2006 India CipDS 20 [S] 25 [S] 8 [S/S] 0.125 [S/S] Tyr464 Non-H58 X3
07-6086 2007 Tunisia Pansusceptible 16 [I] 31 [S] 16 [I/S] 0.047 [S/S] WT ND ND
08-7675† 2008 India ASCSulTmpSXTCipDS 18 [I] 28 [S] 8 [S/S] 0.125 [S/S] Phe464 H58 X1
09-1986† 2008 India ASCSulTmpSXTCipDS 18 [I] 27 [S] 8 [S/S] 0.125 [S/S] Phe464 ND X1
09-0350 2009 Unknown CipDS 19 [I] 27 [S] 8 [S/S] 0.125 [S/S] Phe464 Non-H58 X5
09-2317 2009 French Guyana Pansusceptible 19 [I] 32 [S] 8 [S/S] 0.032 [S/S] Glu468 Non-H58 X4

*PFGE, pulsed-field gel electrophoresis; Nal, nalidixic acid; Cip, ciprofloxacin; WT, wild type; ND, not determined; A, ampicillin; S, streptomycin, C, chloramphenicol; Su, sulfamethoxazole; Tmp, trimethoprim; SXT, cotrimoxazole; CipDS, decreased susceptibility to ciprofloxacin. Disk diffusion test was performed and interpreted ([S], susceptible; [I], intermediate) following recommendations of antibiogram committee of the French Society for Microbiology. MICs were determined by Etest strips, and categorization was made according to the French Society for Microbiology and Clinical and Laboratory Standards Institute.
†Previously described same patient (13).

Main Article

References
  1. Crump  JA, Mintz  ED. Global trends in typhoid and paratyphoid fever. Clin Infect Dis. 2010;50:2416. DOIPubMed
  2. Wain  J, Kidgell  C. The emergence of multidrug resistance to antimicrobial agents for the treatment of typhoid fever. Trans R Soc Trop Med Hyg. 2004;98:42330. DOIPubMed
  3. Wain  J, Hoa  NT, Chinh  NR, Vinh  H, Everett  MJ, Diep  TS, Quinolone-resistant Salmonella typhi in Vietnam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis. 1997;25:140410. DOIPubMed
  4. Roumagnac  P, Weill  FX, Dolecek  C, Baker  S, Brisse  S, Chinh  NT, Evolutionary history of Salmonella Typhi. Science. 2006;314:13014. DOIPubMed
  5. Le  TA, Fabre  L, Roumagnac  P, Grimont  PA, Scavizzi  MR, Weill  FX. Clonal expansion and microevolution of quinolone-resistant Salmonella enterica serotype Typhi in Vietnam from 1996 to 2004. J Clin Microbiol. 2007;45:348592. DOIPubMed
  6. Aarestrup  FM, Wiuff  C, Mølbak  K, Threlfall  EJ. Is it time to change fluoroquinolone breakpoints for Salmonella spp.? Antimicrob Agents Chemother. 2003;47:8279. DOIPubMed
  7. Crump  JA, Kretsinger  K, Gay  K, Hoekstra  RM, Vugia  DJ, Hurd  S, Clinical response and outcome of infection with Salmonella enterica serotype Typhi with decreased susceptibility to fluoroquinolones: a United States FoodNet Multicenter Retrospective Cohort Study. Antimicrob Agents Chemother. 2008;52:127884. DOIPubMed
  8. Crump  JA, Barrett  TJ, Nelson  JT, Angulo  FJ. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae. Clin Infect Dis. 2003;37:7581. DOIPubMed
  9. Booker  BM, Smith  PF, Forrest  A, Bullock  J, Kelchlin  P, Bhavnani  SM, Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype Typhi. Antimicrob Agents Chemother. 2005;49:177581. DOIPubMed
  10. Cooke  FJ, Day  M, Wain  J, Ward  LR, Threlfall  EJ. Cases of typhoid fever imported to England, Scotland and Wales (2000–2003). Trans R Soc Trop Med Hyg. 2007;101:398404. DOIPubMed
  11. Lynch  MF, Blanton  EM, Bulens  S, Polyak  C, Vojdani  J, Stevenson  J, Typhoid fever in the United States, 1999–2006. JAMA. 2009;302:85965. DOIPubMed
  12. Song  Y, Roumagnac  P, Weill  FX, Wain  J, Dolecek  C, Mazzoni  CJ, A multiplex single nucleotide polymorphism typing assay for detecting mutations that result in decreased fluoroquinolone susceptibility in Salmonella enterica serovars Typhi and Paratyphi A. J Antimicrob Chemother. 2010 Jun 1. PMID: 20511368
  13. Gaborieau  V, Weill  FX, Marchou  B. Salmonella enterica serovar Typhi with decreased susceptibility to ciprofloxacin: a case report [in French]. Med Mal Infect. 2010;40:6915. DOIPubMed
  14. Sjölund-Karlsson  M, Howie  R, Rickert  R, Krueger  A, Tran  TT, Zhao  S, Plasmid-mediated quinolone resistance among non-Typhi Salmonella enterica isolates, USA. Emerg Infect Dis. 2010;16:178991.PubMed

Main Article

Page created: August 03, 2011
Page updated: August 03, 2011
Page reviewed: August 03, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external